Serum CYFRA21-1 as a prognostic marker for patients with undifferentiated nasopharyngeal carcinoma

Biomarkers. 2010 Nov;15(7):602-7. doi: 10.3109/1354750X.2010.504309. Epub 2010 Aug 21.

Abstract

The purpose of this study was to evaluate the potential of serum CYFRA21-1 and carcinoembryonic antigen (CEA) as prognostic markers in patients with undifferentiated nasopharyngeal carcinoma. Sixty-one patients who received definitive radiotherapy/chemoradiotherapy were analysed retrospectively. We investigated the association of the follow-up results with pretreatment level, post-treatment level and change of serum CYFRA21-1 and CEA, respectively. Patients with low pretreatment CYFRA21-1 had a significantly better overall survival. There were no significant associations among the remaining serum markers, and the survival and recurrence rates on multivariate analysis. The present study shows that pretreatment CYFRA21-1 level is a potential factor for predicting long-term survival.

MeSH terms

  • Adult
  • Antigens, Neoplasm / blood*
  • Biomarkers, Tumor / blood*
  • Carcinoembryonic Antigen / blood
  • Cell Differentiation
  • Female
  • Humans
  • Keratin-19 / blood*
  • Male
  • Middle Aged
  • Nasopharyngeal Neoplasms / blood*
  • Nasopharyngeal Neoplasms / pathology
  • Prognosis
  • Retrospective Studies

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Keratin-19
  • antigen CYFRA21.1